Landmarks in prostate cancer

[1]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[2]  I. Thompson,et al.  Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial , 2018, Journal of the National Cancer Institute.

[3]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[4]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[5]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[6]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.

[7]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[8]  A. Kader,et al.  Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. , 2017, Urologic oncology.

[9]  P. Carroll,et al.  AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer , 2017, The Journal of urology.

[10]  M. Cooperberg.  The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. , 2017, European urology.

[11]  T. Wilt,et al.  Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer , 2017, The New England journal of medicine.

[12]  Y. Park,et al.  LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. , 2017 .

[13]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[14]  K. Bibbins-Domingo,et al.  The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. , 2017, JAMA.

[15]  Jason D. Wright,et al.  Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States , 2017, JAMA oncology.

[16]  M. Cooperberg,et al.  The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. , 2017, European urology.

[17]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[18]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[19]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[20]  C. Abbou,et al.  LAPAROSCOPIC RADICAL PROSTATECTOMY WITH A REMOTE CONTROLLED ROBOT , 2001, The Journal of urology.

[21]  J. Richie,et al.  COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE CANCER: RESULTS OF A MULTICENTER CLINICAL TRIAL OF 6,630 MEN , 1994, The Journal of urology.

[22]  P. J. Donker,et al.  Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. , 1982, The Journal of urology.

[23]  M. Roobol,et al.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA , 2017, Nature Reviews Urology.

[24]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[25]  Christopher E Barbieri,et al.  Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. , 2016, The Journal of urology.

[26]  N. Agarwal,et al.  Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Robert A Gardiner,et al.  Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study , 2016, The Lancet.

[28]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[29]  E. Schaeffer,et al.  Increasing incidence of metastatic prostate cancer in the United States (2004–2013) , 2016, Prostate Cancer and Prostatic Diseases.

[30]  C. Bevan,et al.  Faculty Opinions recommendation of Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. , 2016 .

[31]  M. Stockler,et al.  Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. , 2016, The Lancet. Oncology.

[32]  Andrew J. Vickers,et al.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[34]  C. Reynolds,et al.  US Preventive Services Task Force Recommendation Statement on Screening for Depression in Adults: Not Good Enough. , 2016, JAMA psychiatry.

[35]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[36]  A. Villers,et al.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. , 2016, The Lancet. Oncology.

[37]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[38]  P. Choyke,et al.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[39]  M. Rezaee,et al.  Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012. , 2016, Preventive medicine.

[40]  P. Choyke,et al.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[41]  P. Carroll,et al.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[42]  H. Hricak,et al.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.

[43]  A. Jemal,et al.  Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. , 2015, JAMA.

[44]  W. J. Morris,et al.  Low-Dose-Rate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavourable Risk Prostate Cancer: The Results of the ASCENDE-RT* Randomized Control Trial , 2015 .

[45]  G. Andriole,et al.  Prostate cancer: A simplified prostate cancer grading system , 2015, Nature reviews. Urology.

[46]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[47]  A. Evans,et al.  Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. , 2015, The Journal of urology.

[48]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[49]  N. Corcoran,et al.  Adverse effects of androgen‐deprivation therapy in prostate cancer and their management , 2015, BJU international.

[50]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[51]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[52]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[53]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[55]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[56]  Tian Liu,et al.  Comparison of Image-guided Radiotherapy Technologies for Prostate Cancer , 2014, American journal of clinical oncology.

[57]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[59]  N. Lawrentschuk,et al.  Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? , 2014, BJU international.

[60]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[61]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[62]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[63]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment. , 2014, European urology.

[64]  L. Walker,et al.  Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. , 2013, Clinical genitourinary cancer.

[65]  Nathan Lawrentschuk,et al.  Transperineal biopsy of the prostate—is this the future? , 2013, Nature Reviews Urology.

[66]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[67]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[68]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[69]  L. Bachmann,et al.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.

[70]  N. Keating,et al.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? , 2013, European urology.

[71]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[72]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[73]  J. Stanford,et al.  Long-term functional outcomes after treatment for localized prostate cancer. , 2013, The New England journal of medicine.

[74]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[75]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[76]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[77]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[78]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[79]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[80]  D. Howard.  Declines in prostate cancer incidence after changes in screening recommendations. , 2012, Archives of internal medicine.

[81]  Yipeng Hu,et al.  A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy , 2012, BJU international.

[82]  Fred Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[83]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[84]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[85]  M. Cooperberg,et al.  PSA screening: determinants of primary-care physician practice patterns , 2012, Prostate Cancer and Prostatic Diseases.

[86]  Brett Delahunt,et al.  Gleason grading: past, present and future , 2012, Histopathology.

[87]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, The Lancet.

[88]  Jeffrey P. Cowan,et al.  PSA screening: determinants of primary-care physician practice patterns , 2011, Prostate Cancer and Prostatic Diseases.

[89]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[90]  J. Chin,et al.  Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[92]  M. Cooperberg,et al.  The CAPRA‐S score , 2011, Cancer.

[93]  J. Crowley,et al.  Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .

[94]  L. Holmberg,et al.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. , 2011, The Lancet. Oncology.

[95]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[96]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[97]  N. Lawrentschuk,et al.  Active surveillance for low-risk prostate cancer: an update , 2011, Nature Reviews Urology.

[98]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[99]  John T. Wei,et al.  Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) for Measuring Health-Related Quality of Life Among Prostate Cancer Survivors , 2011 .

[100]  M. Cooperberg,et al.  A Straightforward Tool for Improved Prediction of Outcomes After Radical Prostatectomy , 2011 .

[101]  A. Kibel.  Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95 , 2010 .

[102]  Martin G Sanda,et al.  Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. , 2010, Urology.

[103]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[104]  D. Bolton,et al.  Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. , 2010, The Journal of clinical endocrinology and metabolism.

[105]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[106]  S. Byun,et al.  Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men , 2010, BJU international.

[107]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[108]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[109]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[110]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[111]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. , 2009, European urology.

[112]  D. Samadi,et al.  Robot-Assisted Laparoscopic Radical Prostatectomy: Technique and Outcomes of 700 Cases , 2009, International journal of biomedical science : IJBS.

[113]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[114]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  T. Wilt,et al.  Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. , 2009, Journal of oncology practice.

[116]  P. Albertsen.  Words of wisdom. Re: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. , 2009, European urology.

[117]  T. Wilt,et al.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[119]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[120]  M. Freedman,et al.  Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa , 2009, Infectious Agents and Cancer.

[121]  H. Lepor,et al.  Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. , 2009, The Journal of urology.

[122]  E. Klein,et al.  Risk factors for prostate cancer , 2009, Nature Clinical Practice Urology.

[123]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[124]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[125]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[126]  Athanase Billis,et al.  The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. , 2008, The Journal of urology.

[127]  J. Adolfsson.  Watchful waiting and active surveillance: the current position , 2008, BJU international.

[128]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  G. Pond,et al.  Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study , 2008, Clinical Cancer Research.

[130]  S. Boorjian,et al.  Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. , 2008, The Journal of urology.

[131]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[133]  P. Walsh.  The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. , 2007, The Journal of urology.

[134]  William Webb,et al.  The Current Position , 2007 .

[135]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[136]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[137]  A. Henderson,et al.  Extensive transperineal template biopsies of prostate: modified technique and results. , 2006, Urology.

[138]  W. Ellis,et al.  Improved prostate cancer detection with anterior apical prostate biopsies. , 2006, Urologic oncology.

[139]  M. Zelefsky.  Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) , 2006 .

[140]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[141]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[142]  Kenneth J. Pienta,et al.  Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.

[143]  I. Tannock,et al.  Management of advanced prostate cancer after first-line chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[145]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[146]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[147]  M. Kattan,et al.  Achieving optimal outcomes after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  M. Cooperberg,et al.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.

[149]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[150]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[151]  P. Walther.  The role of radical prostatectomy in the management of prostatic adenocarcinoma , 1989, World Journal of Urology.

[152]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[153]  Joseph A. Smith,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level ⩽4.0 ng per milliliter , 2004 .

[154]  A. Costello,et al.  Anatomical studies of the neurovascular bundle and cavernosal nerves , 2004, BJU international.

[155]  D. Kirk.  Quality of life compared during pharmacological treatments and clinical monitoring for non‐localized prostate cancer: a randomized controlled trial , 2004, BJU international.

[156]  Mani Menon,et al.  Vattikuti Institute prostatectomy: a technique of robotic radical prostatectomy: experience in more than 1000 cases. , 2004, Journal of endourology.

[157]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[158]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[159]  R. Stock,et al.  Combined modality treatment in the management of high-risk prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[160]  Paul W Dickman,et al.  Natural history of early, localized prostate cancer. , 2004, JAMA.

[161]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[162]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[163]  R. Gardiner,et al.  Quality of life compared during pharmacological treatments and clinical monitoring for non‐localized prostate cancer: a randomized controlled trial , 2004, BJU international.

[164]  P. Humphrey,et al.  Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.

[165]  C. Parker.  Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.

[166]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[167]  J. Montie,et al.  Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D. , 2004, Urology.

[168]  Samir S Taneja,et al.  Imaging in the diagnosis and management of prostate cancer. , 2004, Reviews in urology.

[169]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[170]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[171]  Robert W Veltri,et al.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. , 2003, The Journal of urology.

[172]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[173]  J. Kurhanewicz,et al.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer , 2002, Journal of magnetic resonance imaging : JMRI.

[174]  M. Zelefsky,et al.  Intensity-modulated radiation therapy for prostate cancer. , 2002, Seminars in radiation oncology.

[175]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[176]  Hugh H. Young,et al.  The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases , 2002 .

[177]  H. Young.  The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. , 2002, The Journal of urology.

[178]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[179]  D. Piers,et al.  Routine bone scans in patients with prostate cancer related to serum prostate‐specific antigen and alkaline phosphatase , 2001, BJU international.

[180]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[181]  B. Guillonneau,et al.  Laparoscopic radical prostatectomy: the Montsouris technique. , 2000, The Journal of urology.

[182]  C. Newschaffer,et al.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.

[183]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[184]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[185]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[187]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[188]  P. Hosking,et al.  A histological study of Denonvilliers' fascia and its relationship to the neurovascular bundle. , 1998, British journal of urology.

[189]  R H Brook,et al.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.

[190]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[191]  J. Melamed,et al.  Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. , 1998, The Journal of urology.

[192]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[193]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[194]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[195]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[196]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[197]  H A Feldman,et al.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. , 1994, The Journal of urology.

[198]  A. Wozniak,et al.  Cyclophosphamide, methotrexate, and 5‐fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study , 1993, Cancer.

[199]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[200]  P. Humphrey,et al.  Immunoreactive prostatic specific antigen in male periurethral glands. , 1992, The Journal of urology.

[201]  J. Mckinlay,et al.  Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. , 1991, The Journal of clinical endocrinology and metabolism.

[202]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[203]  S. Goldenberg,et al.  Use of cyproterone acetate in prostate cancer. , 1991, The Urologic clinics of North America.

[204]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[205]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[206]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[207]  T H Beaty,et al.  Family history and the risk of prostate cancer , 1990, The Prostate.

[208]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[209]  T. Stamey,et al.  Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. , 1989, The Journal of urology.

[210]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[211]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[212]  P. Walsh,et al.  The role of radical prostatectomy in the management of prostatic cancer , 1987, Cancer.

[213]  D. Trump,et al.  Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  R B Jeffrey,et al.  Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. , 1987, Radiology.

[215]  K. Johnson.  An Update. , 1984, Journal of food protection.

[216]  C. Foo,et al.  A REPORT OF 20 CASES , 1983 .

[217]  Herbert Lepor,et al.  Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations , 1983, The Prostate.

[218]  P. J. Donker,et al.  Impotence following radical prostatectomy: insight into etiology and prevention. , 1982, The Journal of urology.

[219]  F. Labrie,et al.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. , 1982, Clinical and investigative medicine. Medecine clinique et experimentale.

[220]  J. McNeal.  The zonal anatomy of the prostate , 1981, The Prostate.

[221]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[222]  J. Mulcahy,et al.  Carcinoma of the prostate. , 1978, The Journal of the Kentucky Medical Association.

[223]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[224]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[225]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[226]  D. Gleason.  Classification of prostatic carcinomas. , 1966, Cancer chemotherapy reports.

[227]  H. Kaplan,et al.  LINEAR ACCELERATOR SUPERVOLTAGE RADIOTHERAPY. VII. CARCINOMA OF THE PROSTATE. , 1965, Radiology.

[228]  T. Millen,et al.  RETROPUBIC URINARY SURGERY , 1947, The Ulster Medical Journal.

[229]  T. Millin.  Retropubic prostatectomy; a new extravesical technique; report of 20 cases. , 1945, Lancet.

[230]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[231]  J. McNeal,et al.  The zonal anatomy of the prostate , 1981, The Prostate.